These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37313228)

  • 21. Aripiprazole IM depot as an option for the treatment of bipolar disorder.
    Kotzalidis GD; Rapinesi C; Chetoni C; De Filippis S
    Expert Opin Pharmacother; 2021 Aug; 22(11):1407-1416. PubMed ID: 33847183
    [No Abstract]   [Full Text] [Related]  

  • 22. Metabolic and Endocrine Profiles During 1-Year Treatment of Outpatients with Schizophrenia with Aripiprazole Lauroxil.
    Nasrallah HA; Aquila R; Stanford AD; Jamal HH; Weiden PJ; Risinger R
    Psychopharmacol Bull; 2017 Aug; 47(3):35-43. PubMed ID: 28839338
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aripiprazole once-monthly long-acting injectable for the treatment of schizophrenia.
    Potkin SG; Preda A
    Expert Opin Pharmacother; 2016; 17(3):395-407. PubMed ID: 26864352
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia.
    Turncliff R; Hard M; Du Y; Risinger R; Ehrich EW
    Schizophr Res; 2014 Nov; 159(2-3):404-10. PubMed ID: 25266547
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population Pharmacokinetic Analysis and Model-Based Simulations of Aripiprazole for a 1-Day Initiation Regimen for the Long-Acting Antipsychotic Aripiprazole Lauroxil.
    Hard ML; Wehr AY; Sadler BM; Mills RJ; von Moltke L
    Eur J Drug Metab Pharmacokinet; 2018 Aug; 43(4):461-469. PubMed ID: 29943125
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aripiprazole Lauroxil Dosing Regimens: Understanding Dosage Strengths and Injection Intervals.
    Sommi RW; Rege B; Wehr A; Faldu S; Du Y; Weiden PJ
    CNS Spectr; 2022 Jun; 27(3):262-267. PubMed ID: 33267924
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Phase-1 Study Comparing Pharmacokinetic and Safety Profiles of Three Different Dose Intervals of Aripiprazole Lauroxil.
    Risinger R; Hard M; Weiden PJ
    Psychopharmacol Bull; 2017 Aug; 47(3):26-34. PubMed ID: 28839337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aripiprazole Lauroxil Long-Acting Injectable: The Latest Addition to Second-Generation Long-Acting Agents.
    Aggarwal A; Gopalakrishna G; Lauriello J
    Clin Schizophr Relat Psychoses; 2016; 10(1):58-63. PubMed ID: 27074333
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Size matters: the importance of particle size in a newly developed injectable formulation for the treatment of schizophrenia.
    Jain R; Meyer J; Wehr A; Rege B; von Moltke L; Weiden PJ
    CNS Spectr; 2020 Jun; 25(3):323-330. PubMed ID: 31111801
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Best Practices for Aripiprazole Lauroxil Administration: From Formulation Development to Injection Technique.
    Farwick S; Hickey MB; Jacobs G; Faldu SP; Vandiver J; Weiden PJ
    J Psychiatr Pract; 2019 Mar; 25(2):82-90. PubMed ID: 30849056
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Second-generation long-acting injections anti-psychotics improve executive functions in patients with schizophrenia: a 12-month real-world study.
    Magliocco F; de Filippis R; Aloi M; Staltari FA; Gaetano R; Segura-Garcia C; De Fazio P
    Int J Psychiatry Clin Pract; 2020 Jun; 24(2):201-207. PubMed ID: 32134336
    [No Abstract]   [Full Text] [Related]  

  • 32. Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents.
    Jann MW; Penzak SR
    CNS Drugs; 2018 Mar; 32(3):241-257. PubMed ID: 29569082
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aripiprazole Lauroxil Compared with Paliperidone Palmitate in Patients with Schizophrenia: An Indirect Treatment Comparison.
    Cameron C; Zummo J; Desai DN; Drake C; Hutton B; Kotb A; Weiden PJ
    Value Health; 2017; 20(7):876-885. PubMed ID: 28712616
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
    Tempest M; Sapin C; Beillat M; Robinson P; Treur M
    J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy, tolerability, and safety of aripiprazole once-monthly versus other long-acting injectable antipsychotic therapies in the maintenance treatment of schizophrenia: a mixed treatment comparison of double-blind randomized clinical trials.
    Majer IM; Gaughran F; Sapin C; Beillat M; Treur M
    J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123183
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase Schizophrenia: A Randomized Clinical Trial.
    Kane JM; Schooler NR; Marcy P; Correll CU; Achtyes ED; Gibbons RD; Robinson DG
    JAMA Psychiatry; 2020 Dec; 77(12):1217-1224. PubMed ID: 32667636
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aripiprazole Lauroxil, a Novel Injectable Long-Acting Antipsychotic Treatment for Adults with Schizophrenia: A Comprehensive Review.
    Maini K; Gould H; Hicks J; Iqbal F; Patterson J; Edinoff AN; Cornett EM; Kaye AM; Viswanath O; Urits I; Kaye AD
    Neurol Int; 2021 Jul; 13(3):279-296. PubMed ID: 34287335
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole.
    Potkin SG; Raoufinia A; Mallikaarjun S; Bricmont P; Peters-Strickland T; Kasper W; Baker RA; Eramo A; Sanchez R; McQuade R
    Curr Med Res Opin; 2013 Oct; 29(10):1241-51. PubMed ID: 23822566
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report.
    Eum S; Schneiderhan ME; Brown JT; Lee AM; Bishop JR
    BMC Psychiatry; 2017 Jul; 17(1):238. PubMed ID: 28673279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-acting injectable antipsychotics update: lengthening the dosing interval and expanding the diagnostic indications.
    Citrome L
    Expert Rev Neurother; 2017 Oct; 17(10):1029-1043. PubMed ID: 28832262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.